Dr. Abdulwasiu Bolaji Tiamiyu, Deputy Director of Research in Nigeria, in November graduated from the Harvard Medical School Global Clinical Scholars Training (GCSRT), an advanced training program research for clinicians and clinician-scientists around the globe.
SILVER SPRING, Md. – Some recent reports about Walter Reed Army Institute of Research’s COVID-19 Vaccine Development have led to inaccurate representations which require clarification. Last week, the preclinical results of the Army COVID-19 vaccine, SpFN, were published in Science Translational Medicine. The Spike Ferritin Nanoparticle platform is designed to protect against an array of SARS-CoV-2 variants and SARS-origin variants but was not tested on the Omicron variant.
A series of recently published preclinical study results show that the Spike Ferritin Nanoparticle (SpFN) COVID-19 vaccine developed by researchers at the Walter Reed Army Institute of Research may provide broad protection against SARS-CoV-2 variants of concern as well as other coronaviruses.
COVID-19 outbreaks in military populations threaten force health and readiness, and basic training presents particular challenges. A new publication co-authored by WRAIR scientists and posted on the preprint server medRxiv outlines improved strategies for preventing outbreaks during basic training, emphasizing the need for customized approaches in unique settings.
A study conducted by researchers with the Emerging Infectious Diseases Branch (EIDB) of the Walter Reed Army Institute of Research (WRAIR) identified monoclonal antibodies targeting different areas of the SARS-CoV-2 spike protein that in combination provided broad neutralizing protection while preventing viral escape. Findings were published last week in Nature Immunology.
Prolonged COVID-19 infection among immune compromised individuals may generate multiple mutations of SARS-CoV-2, providing a path to more transmissible or virulent variants of concern. Researchers describe some implications of SARS-CoV-2 evolution in immunosuppressed patients in a new commentary in the New England Journal of Medicine.